Carmustine-loaded catanionic solid lipid nanoparticles with serotonergic 1B receptor subtype antagonist for in vitro targeted delivery to inhibit brain cancer growth

Journal of the Taiwan Institute of Chemical Engineers

Volumn 46, Issue , 2015, Pages 1-14

  Kuo, Yung Chih ^a   Wang, Cheng Chin ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Blood brain barrier; Carmustine; Catanionic surfactant; Serotonergic 1B receptor subtype antagonist; Solid lipid nanoparticle; U87MG cell

Indexed keywords

BLOOD; CELLS; CYTOLOGY; EFFICIENCY; GRAFTING (CHEMICAL); MICROEMULSIONS; NANOPARTICLES; PARTICLE SIZE; SURFACE ACTIVE AGENTS;

BLOOD-BRAIN BARRIER; CARMUSTINE; CATANIONIC SURFACTANTS; SEROTONERGIC 1B RECEPTOR SUBTYPE ANTAGONIST; SOLID LIPID NANOPARTICLE (SLN);

ENDOTHELIAL CELLS;

EID: 84920364360     PISSN: 18761070     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtice.2014.08.035     Document Type: Article

References (97)

1. Argyriou A.A., Antonacopoulou A., Iconomou G., Kalofonos H.P. Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 2009, 69:199-210.
2. Halatsch M.E., Schmidt U., Behnke-Mursch J., Unterberg A., Wirtz C.R. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006, 32:74-89.
3. Kuo Y.C., Ko H.F. Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles. Biomaterials 2013, 34:4818-4830.
4. Lin D., Parsons L.H. Anxiogenic-like effect of serotonin (1B) receptor stimulation in the rat elevated plus-maze. Pharmacol Biochem Behav 2002, 71:581-587.
5. O'Connor J.J., Kruk Z.L. Effects of 21 days treatment with fluoxetine on stimulated endogenous 5-hydroxytryptamine overflow in the rat dorsal raphe and suprachiasmatic nucleus studied using fast cyclic voltammetry in vitro. Brain Res 1994, 640:328-335.
6. Anthony J.P., Sexton T.J., Neumaier J.F. Antidepressant-induced regulation of 5-HT(1b) mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. J Neurosci Res 2000, 61:82-87.
7. Gobert A., Rivet J.M., Cistarelli L., Millan M.J. Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935. J Neurochem 1997, 68:1159-1163.
8. Tomkins D.M., O'Neill M.F. Effect of 5-HT(1B) receptor ligands on self-administration of ethanol in an operant procedure in rats. Pharmacol Biochem Behav 2000, 66:129-136.
9. Sollars P.J., Ogilvie M.D., Simpson A.M., Pickard G.E. Photic entrainment is altered in the 5-HT1B receptor knockout mouse. J Biol Rhythms 2006, 21:21-32.
10. Grimaldi B., Bonnin A., Fillion M.P., Prudhomme N., Fillion G. 5-HT moduline: a novel endogenous peptide involved in the control of anxiety. Neuroscience 1999, 93:1223-1225.
11. Mehnert W., Mader K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Delivery Rev 2001, 47:165-196.
12. Miglietta A., Cavalli R., Bocca C., Gabriel L., Gasco M.R. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000, 210:61-67.
13. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
14. Wissing S.A., Kayser O., Muller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Delivery Rev 2004, 56:1257-1272.
15. Kuo Y.C., Chung J.F. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloids Surf, B: Biointerfaces 2011, 83:299-306.
16. Kuo Y.C., Liang C.T. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 2011, 32:3340-3350.
17. Kuo Y.C., Wang L.J. Transferrin-grafted catanionic solid lipid nanoparticles for targeting delivery of saquinavir to the brain. J Taiwan Inst Chem Eng 2014, 45:755-763.
18. Walker M.D., Hilton J. Nitrosourea pharmacodynamics in relation to the central nervous system. Cancer Treat Rep 1976, 60:725-728.
19. Liu H.L., Fan C.H., Ting C.Y., Yeh C.K. Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview. Theranostics 2014, 4:432-444.
20. Chae G.S., Lee J.S., Kim S.H. Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer. Int J Pharm 2005, 301:6-14.
21. Xu X., Chen X., Xu X., Lu T., Wang X., Yang L., et al. BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against glioma C6 cells. J Controlled Release 2006, 114:307-316.
22. Loo T.L., Dion R.L., Dixon R.L., Rall D.P. The antitumor agent, 1,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci 1966, 55:492-497.
23. Hansen R.J., Nagasubramanian R., Delaney S.M., Cherian M.M., Lin S., Kogan S.C., et al. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. J Pharmacol Exp Ther 2005, 315:1247-1255.
24. Kornblith P.L., Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988, 68:1-17.
25. Rhines L.D., Sampath P., Dolan M.E., Tyler B.M., Brem H., Weingart J. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 2000, 60:6307-6310.
26. 6-benzylguanine shell for glioma therapy. Biomaterials 2013, 34:8968-8978.
27. Han L., Ren Y., Long L., Zhong Y., Shen C., Pu P., et al. Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles. Oncol Rep 2012, 27:121-128.
28. Park J.H., Kim H.A., Cho S.H., Lee M. Characterization of hydrophobic anti-cancer drug-loaded amphiphilic peptides as a gene carrier. J Cell Biochem 2012, 113:1645-1653.
29. Yang H.W., Hua M.Y., Liu H.L., Huang C.Y., Tsai R.Y., Lu Y.J., et al. Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. Biomaterials 2011, 32:6523-6532.
30. Hua M.Y., Liu H.L., Yang H.W., Chen P.Y., Tsai R.Y., Huang C.Y., et al. The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas. Biomaterials 2011, 32:516-527.
31. Jones S.J., Dinsmore J. Effect of diclofenac on cerebral blood flow velocity in patients with supratentorial tumours. Br J Anaesth 2002, 89:762-764.
32. Kuo Y.C., Wang C.C. Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia. Colloids Surf, B: Biointerfaces 2013, 101:101-105.
33. ®) wafers in the treatment of malignant gliomas. Ther Clin Risk Manage 2007, 3:707-715.
34. Urban-Morlan Z., Ganem-Rondero A., Melgoza-Contreras L.M., Escobar-Chavez J.J., Nava-Arzaluz M.G., Quintanar-Guerrero D. Preparation charcterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method. Int J Nanomed 2010, 5:611-620.
35. Barandeh F., Nguyen P.L., Kumar R., Iacobucci G.J., Kuznicki M.L., Kosterman A., et al. Organically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivo. PLoS One 2012, 7:29424.
36. Kuo Y.C., Shih-Huang C.Y. Solid lipid nanoparticles with surface antibody for targeting the brain and inhibiting lymphatic phagocytosis. J Taiwan Inst Chem Eng 2014, 45:1154-1163.
37. Kuo Y.C., Wang C.C. Surface molecular composition and electrical property of cationic solid lipid nanoparticles with assembled lipid layer mediated by noncovalent interactions. J Phys Chem C 2012, 116:16999-17007.
38. Freitas C., Muller R.H. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm 1998, 168:221-229.
39. Bhandari R., Kaur I.P. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm 2013, 441:202-212.
40. Kuo Y.C., Chen I.C. Evaluation of surface charge density and surface potential by electrophoretic mobility for solid lipid nanoparticles and human brain microvascular endothelial cells. J Phys Chem B 2007, 111:11228-11236.
41. Kuo Y.C., Lu C.H. Regulation of endocytosis into human brain-microvascular endothelial cells by inhibition of efflux proteins. Colloids Surf, B: Biointerfaces 2011, 87:139-145.
42. Chung C.Y., Yang J.T., Kuo Y.C. Polybutylcyanoacrylate nanoparticles for delivering hormone response element-conjugated neurotrophin-3 to the brain of intracerebral hemorrhagic rats. Biomaterials 2013, 34:9717-9727.
43. Kondo T., Wada K., Kawashima M., Sato Y., Yamauchi M. High-sensitivity drug sensitivity testing. Oncology 1994, 51:535-539.
44. Crowell S.R., Henderson W.M., Fisher J.W., Kenneke J.F. Gender and species differences in triadimefon metabolism by rodent hepatic microsomes. Toxicol Lett 2010, 193:101-107.
45. Yu L.S., Yao T.W., Zeng S. In vitro metabolism of zolmitriptan in rat cytochromes induced with β-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact 2003, 146:263-272.
46. Gunaratna C. Drug metabolism and pharmacokinetics in drug discovery: a primer for bioanalytical chemists, Part II. Curr Sep 2001, 19:87-92.
47. Smith M.T., Evans C.G., Doane-Setzer I., Castro V.M., Tahir M.K., Mannervik B. Denitrosation of 1,3-bis(2-chloroethyl)-l-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res 1989, 49:2621-2625.
48. Kuo Y.C., Lu C.H. Effect of human astrocytes on the characteristics of human brain-microvascular endothelial cells in the blood-brain barrier. Colloids Surf, B: Biointerfaces 2011, 86:225-231.
49. Kuo Y.C., Wang C.C. Cationic solid lipid nanoparticles with cholesterol-mediated surface layer for transporting saquinavir to the brain. Biotechnol Prog 2014, 30:198-206.
50. Kuo Y.C., Lu C.H. Expression of P-glycoprotein and multidrug resistance-associated protein on human brain-microvascular endothelial cells with electromagnetic stimulation. Colloids Surf, B: Biointerfaces 2012, 91:57-62.
51. Kuo Y.C., Wang C.T. Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin. Biomaterials 2014, 35:5954-5964.
52. Kuo Y.C., Hong T.Y. Delivering etoposide to the brain using catanionic solid lipid nanoparticles with surface 5-HT-moduline. Int J Pharm 2014, 465:132-142.
53. Chitra K., Annadurai G. Fluorescent silica nanoparticles in the detection and control of the growth of pathogen. J Nanotechnol 2013, 2013:509628.
54. Hac-Wydro K., Wydro P. The influence of fatty acids on model cholesterol/phopholipid membranes. Chem Phys Lipids 2007, 150:66-81.
55. Kuo Y.C., Shih-Huang C.Y. Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway. J Drug Target 2013, 21:730-738.
56. Lopez-Fontan J.L., Blanco E., Ruso J.M., Prieto M., Schulz P.C., Sarmiento F. The aqueous catanionic system sodium perfluorooctanoate-dodecyltrimethylammonium bromide at low concentration. J Colloid Interface Sci 2007, 312:425-431.
57. Aiello C., Andreozzi P., Mesa C.L., Risuleo G. Biological activity of SDS-CTAB cat-anionic vesicles in cultured cells and assessment of their cytotoxicity ending in apoptosis. Colloids Surf, B: Biointerfaces 2010, 78:149-154.
58. Kuo Y.C., Liang C.T. Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells. Colloids Surf, B: Biointerfaces 2011, 85:131-137.
59. Teeranachaideekul V., Muller R.H., Junyaprasertv V.B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int J Pharm 2007, 340:198-206.
60. Liu Y.S., Wen C.F., Yang Y.M. Development of ethosome-like catanionic vesicles for dermal drug delivery. J Taiwan Inst Chem Eng 2012, 43:830-838.
61. Maiti K., Bhattacharya S.C., Moulik S.P., Panda A.K. Physicochemistry of the binary interacting mixtures of cetylpyridinium chloride (CPC) and sodium dodecylsulfate (SDS) with special reference to the catanionic ion-pair (coacervate) behavior. Colloids Surf, A: Physicochem Eng Aspects 2010, 355:88-98.
62. Kuo Y.C., Lin S.C. Effect of glutamate on the electrical properties of cationic solid lipid nanoparticles containing stearylamine and dioctadecyldimethyl ammonium bromide. J Phys Chem B 2008, 112:4454-4460.
63. Chakraborty H., Sarkar M. Optical spectroscopic and TEM studies of catanionic micelles of CTAB/SDS and their interaction with a NSAID. Langmuir 2004, 20:3551-3558.
64. Ger M.D. Electrochemical deposition of nickel/SiC composites in the presence of surfactants. Mater Chem Phys 2004, 87:67-74.
65. Sohrabi B., Gharibi H., Tajik B., Javadian S., Hashemianzadeh M. Molecular interactions of cationic and anionic surfactants in mixed monolayers and aggregates. J Phys Chem B 2008, 112:14869-14876.
66. Loisel C., Keller G., Lecq G., Bourgaux C., Ollivon M. Phase transitions and polymorphism of cocoa butter. J Am Oil Chem Soc 1998, 75:425-439.
67. Shi F., Zhao J.H., Liu Y., Wang Z., Zhang Y.T., Feng N.P. Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil. Int J Nanomed 2012, 7:2033-2043.
68. Bhalekar M.R., Pokharkar V., Madgulkar A., Patil N., Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 2009, 10:289-296.
69. Fathi M., Varshosaz J., Mohebbi M., Shahidi F. Hesperetin-loaded solid lipid nanoparticles and nanostructure lipid carriers for food fortification: preparation, characterization, and modeling. Food Bioprocess Technol 2013, 6:1464-1475.
70. Larson A.C., Von Dreele R.B. Generalized structure analysis system (GSAS). Los Alamos National Laboratory report LAUR 86-748 1994, Los Alamos National Laboratory, Los Alamos, NM.
71. Ramimoghadam D., Hussain M.Z.B., Taufiq-Yap Y.H. The effect of sodium dodecyl sulfate (SDS) and cetyltrimethylammonium bromide (CTAB) on the properties of ZnO synthesized by hydrothermal method. Int J Mol Sci 2013, 13:13275-13293.
72. Schulz J.C., Warr G.G. Adsorbed layer structure of cationic and anionic surfactants on mineral oxide surfaces. Langmuir 2002, 18:3191-3197.
73. Callewaert M., Dukic S., van Gulick L., Vittier M., Gafa V., Andry M.C., et al. Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency. J Biomed Mater Res A 2013, 101:1319-1327.
74. Hou D.Z., Xie C.S., Huang K.J., Zhu C.H. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003, 24:1781-1785.
75. Kuo J.S., Chang C.H., Lin Y.L., Wu C.J. Flow cytometric characterization of interactions between U-937 human macrophages and positively charged catanionic vesicles. Colloids Surf, B: Biointerfaces 2008, 64:307-313.
76. Jones C.F., Grainger D.W. In vitro assessments of nanomaterial toxicity. Adv Drug Delivery Rev 2009, 61:438-456.
77. Kuo Y.C., Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 2007, 340:143-152.
78. Scholer N., Hahn H., Muller R.H., Liesenfeid O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002, 231:167-176.
79. Muller R.H., Maassen S., Weyhers H., Specht F., Lucks J.S. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 1996, 138:85-94.
80. Allison A.C., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974, 252:252.
81. Lutz O., Meraihi Z., Mura J.L., Frey A., Riess G.H., Bach A.C. Fat emulsion particle size: influence on the clearance rate and the tissue lipolytic activity. Am J Clin Nutr 1989, 50:1370-1381.
82. Simone E.A., Dziubla T.D., Muzykantov V.R. Polymeric carriers: role of geometry in drug delivery. Expert Opin Drug Delivery 2008, 5:1283-1300.
83. Kuo Y.C., Lin P.I., Wang C.C. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Nanomedicine 2011, 6:1011-1026.
84. Morris M.J., Pandit-Taskar N., Divgi C.R., Bender S., O'Donoghue J.A., Nacca A., et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 2007, 13:2707-2713.
85. Gaillard P.J., de Boer A.G. Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci 2000, 12:95-102.
86. Flecher N.F., Brayden D.J., Brankin B., Worrall S., Callanan J.J. Growth and characterisation of a cell culture model of the feline blood-brain barrier. Vet Immunol Immunopathol 2006, 109:233-244.
87. Callahan M.K., Williams K.A., Kivisakk P., Pearce D., Stins M.F., Ransohoff R.M. CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J Neuroimmunol 2004, 153:150-157.
88. Golden P.L., Maccagnan T.J., Pardridge W.M. Human blood-brain barrier leptin receptor: binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997, 99:14-18.
89. Kuo Y.C., Lin C.W. Impact of arginine-modified solid lipid nanoparticles on the membrane charge of human brain-microvascular endothelial cells. Colloids Surf, B: Biointerfaces 2009, 72:201-207.
90. van Bree J.B.M.M., de Boer A.G., Danhof M., Ginsel L.A., Breimer D.D. Characterization of an in vitro blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 1998, 247:1233-1239.
91. Fontana G., Licciardi M., Mansueto S., Schillaci D., Giammona G. Amoxicillin-loaded polyethylcyano-acrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 2001, 22:2857-2865.
92. Klose D., Siepmann F., Elkharraz K., Krenzlin S., Siepmann J. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int J Pharm 2006, 314:198-206.
93. Kuo Y.C., Kuo C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int J Pharm 2008, 351:271-281.
94. Caraglia M., Marra M., Mancinelli F., D'Ambrosio G., Massa R., Giordano A., et al. Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi-chaperone complex in human epidermoid cancer cells. J Cell Physiol 2005, 204:539-548.
95. 1B antimigraine drug receptor in rat and human brain microvessels. Neuroscience 1998, 86:1031-1035.
96. 1B receptor agonist reduces serotonin synthesis following acute, and not chronic, drug administration: results of an autoradiographic study. Neurochem Int 2005, 46:261-272.
97. Kaumann A.J., Levy F.O. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 2006, 111:674-706.